<DOC>
	<DOCNO>NCT02857426</DOCNO>
	<brief_summary>The purpose study determine whether Nivolumab effective treatment Relapsed/Refractory Primary Central Nervous System Lymphoma ( PCNSL ) Relapsed/Refractory Primary Testicular Lymphoma ( PTL )</brief_summary>
	<brief_title>A Study Nivolumab Relapsed/Refractory Primary Central Nervous System Lymphoma ( PCNSL ) Relapsed/Refractory Primary Testicular Lymphoma ( PTL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Pathologically confirm PCNSL PTL fail respond least 1 line systemic therapy Measurable disease requirement scan : PCNSL subject least one measurable extranodal brain lesion ; PTL subject least 1 measurable extranodal lesion . Have tumor tissue PDL1 expression test Must Karnofsky performance status 70100 ) Intraocular PCNSL without evidence brain disease b ) PCNSL patient undergo MRI assessment c ) PCNSL patient systemic disease Patients certain disease active autoimmune disease , type I diabetes , hypothyroidism need hormone replacement , active infection , psychiatric disorder Prior malignancy active within previous 3 year except locally curable cancer apparently cure , basal squamous cell skin cancer , superficial bladder cancer , carcinoma situ prostate , cervix , breast Prior treatment antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCTLA4 antibody , antibody drug specifically target Tcell costimulation checkpoint pathways Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>